Press Release
atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia
NEW YORK , Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences  ("atai" or the "Company") , a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with  Massachusetts General Hospital
Press Release
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
Dr. Rolando Gutierrez-Esteinou & Greg Weaver to Join Executive Management Team NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"),  a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced
Press Release
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
Funding to support advancement of psychedelic and non-psychedelic compounds as well as innovative technologies to treat mental health disorders Participants include Apeiron Investment Group, Peter Thiel, Catalio Capital Management, Future Ventures, Galaxy Investment Partners, Falcon Edge Capital
Press Release
ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic
NEW YORK, Oct. 27, 2020 /PRNewswire/ --  ATAI Life Sciences ("ATAI" or the "Company"), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. ("Neuronasal") has completed its pilot study
Press Release
ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product
NEW YORK, Aug. 24, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company") , a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of 
Press Release
ATAI and IntelGenx enter into Feasibility Agreement to develop pharmaceutical-grade polymeric film technologies for delivery of psychedelic medicines
NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental health indications, announced a Feasibility Agreement with IntelGenx Corp.
Displaying 97 - 102 of 110